Daewha Pharmaceutical made IND application of Phase 2 clinical trial for breast cancer to FDA

Daehwa Pharmaceutical announced on the 18^th that the company completed the IND(Investigational New Drug) application process for a Phase 2 clinical trial of paclitaxel, an oral anti-cancer drug(Korean product name: Liporaxel Soln), to conduct a clinical trial on breast cancer patients in the U.S.

Liporaxel was recognized as the world’s first oral paclitaxel product as acquiring a commercializa...